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Abstract
Ischemic stroke is the most common cerebrovascular disease and considered as a worldwide leading cause of death. After 
cerebral ischemia, different pathophysiological processes including neuroinflammation, invasion and aggregation of inflam-
matory cells and up-regulation of cytokines occur simultaneously. In this respect, Toll-like receptors (TLRs) are the first 
identified important mediators for the activation of the innate immune system and are widely expressed in glial cells and 
neurons following brain trauma. TLRs are also able to interact with endogenous and exogenous molecules released during 
ischemia and can increase tissue damage. Particularly, TLR2 and TLR4 activate different downstream inflammatory signal-
ing pathways. In addition, TLR signaling can alternatively play a role for endogenous neuroprotection. In this review, the 
gene and protein structures, common genetic polymorphisms of TLR2 and TLR4, TLR-related molecular pathways and 
their putative role after ischemic stroke are delineated. Furthermore, the relationship between neurosteroids and TLRs as 
neuroprotective mechanism is highlighted in the context of brain ischemia.
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Introduction
Stroke resulting from focal occlusion of a main artery in 
the brain is considered as the most important cause of dis-
ability in men and a leading cause of death worldwide. Ini-
tial damage after the primary ischemic event is followed 
by delayed metabolic alterations called secondary injury 
mechanisms which can increase excitatory neurotransmitter 
levels, neuronal apoptosis, immune-inflammatory activation 
as well as lipid degradation [1–3]. In this respect, systemic 
and local inflammatory responses play a main role in the 
pathophysiology of cerebral ischemia. The given responses 
can similarly not only increase the ischemic lesion but also 
protect injured tissue [4, 5]. Macrophages, neutrophils, and 
lymphocytes have equally distinct significant roles in dif-
ferent brain inflammatory events even though the under-
lying mechanisms leading to their activation are not fully 
clear. Toll-like receptors (TLRs) are activated in response 
to inflammation and are also recognized as innate immune 
receptors located on the cell surface or inside endosomes 
[4, 6]. Activation of TLRs leads to the initiation of different 
downstream inflammatory cascades. TLR expression can 
also be regulated in response to exogenous microorganisms 
as well as different types of cytokines (chemokines, interfer-
ons, and interleukins) which are secreted in the core and the 
penumbra region of ischemic brain tissue [7, 8]. Expression 
of these mediators depends on nuclear factor-kB (NF-κB) as 
the main transcription factor implicated in the TLR pathway 
[8]. Therefore, these receptors may have an important role 
mediating brain damage following ischemia and are thus 
assumed as clinical targets for preventing secondary injury 
after ischemic stroke [9, 10]. In this review article, we focus 
on the TLR family and their respective ligands, structures, 
and signaling pathways and also point at the role of TLRs 
in ischemic stroke emphasizing the interaction with neuro-
steroids. Moreover, gene and protein structures as well as 
common genetic polymorphisms of TLR2 and TLR4 mole-
cules and their possible roles in stroke-induced inflammatory 
pathways are discussed. Finally, the relationship between 
neurosteroids and TLRs following an ischemic event in the 
brain is underlined as therapeutic targets for stroke therapy.
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TLR family and expression
TLRs are a family of molecules playing a major role in the 
innate immune system [11]. TLR inflammatory responses 
and cytokine secretion typically increase in glial cells and 
leukocytes in response to microorganisms [12]. A total num-
ber of 13 TLRs have been identified until now, of which only 
10 (TLR1-10) have been related to humans [13]. Generally, 
TLR localization and expression depends on the tissue or 
cell type. TLR1, 2, 4, 5, 6, and 10 are localized on the cell 
surface, whereas TLRs 3, 7, 8, and 9 are usually expressed 
exclusively in intracellular compartments such as endosomes 
and lysosomes [14, 15]. Based on their sequence homolo-
gies, human TLRs can be grouped into five subfamilies of 
TLR1/2/6/10, TLR3, TLR4, TLR5, TLR7/8/9 [16, 17]. 
TLRs have also been described as prototype pattern recog-
nition receptors (PRRs) and are able to recognize danger-
associated molecular patterns (DAMPs) or pathogen-asso-
ciated molecular patterns (PAMPs) which are released from 
damaged tissue or microorganisms [18, 19]. It should be 
noted that DAMPs are released or modified and then bound 
to their respective receptors after an inflammatory response. 
DAMPs can also include extracellular matrix fibronectin, 
hyaluronan, heparin sulfate, and even molecules which are 
found in intracellular compartments such as ATP, heat-shock 
proteins, uric acid, and those of nuclear origin such as high 
mobility group box 1 protein (HMGB1), double-strand RNA 
(dsRNA), single-strand RNA (ssRNA), DNA, and microR-
NAs [19, 20]. PAMPs which are recognized by TLRs and 
derived from bacteria, viruses, parasites, and fungi include 
lipids, lipoproteins, proteins as well as nucleic acids [21]. In 
this regard, TLRs on the cell surface are capable to identify 
PAMPs as their ligands, e.g., TLR1/TLR2, TLR2/TLR6, and 
TLR2. TLR4 is considered as a receptor for lipopolysac-
charide (LPS) and myeloid differentiation factor 2 (MD2), 
and TLR5 binds to flagellin. Intracellular TLRs include 
TLR3 which recognizes microbial nucleic acid including 
viral dsRNAs, TLR7, and TLR8 which can interact with 
ssRNAs, and TLR9 which binds to CpG-containing DNA 
[22]. TLRs are expressed in glial cells (microglia, astrocytes, 
oligodendrocytes), neurons in the central nervous system 
(CNS) and peripheral nervous system (PNS) [23–25]. Like-
wise, they are often found in circumventricular organs and 
meninges with direct access to the circulation. TLRs also 
exist on antigen-presenting cells (APCs) in the CNS such 
as dendritic cells, B cells, macrophages, microglia, mono-
cytes, and endothelial cells [26, 27]. Thus, the presence of 
specific TLRs in microglia and astrocytes allows to respond 
in different manner. For instance, microglia can secrete vig-
orous chemokines and cytokines in response to TLR 2, 3, 4 
stimulation, whereas astrocytes can secrete low IL-6 levels 
in response to a stimulation with TLR3 [26].
Structurally, TLRs are categorized as type I integral 
membrane glycoproteins that share a common domain 
structure consisting of an extracellular recognition domain, 
a single transmembrane domain (helix), as well as an intra-
cellular Toll-interleukin 1 receptor (TIR) homology sign-
aling domain [28, 29]. The extracellular domains encom-
pass leucine-rich repeats and mediate the recognition of 
PAMPs, the transmembrane domain and the intracellular 
TIR domains are also essential for triggering downstream 
signaling pathways [15, 30]. The N-terminal ectodomains of 
TLRs are glycoproteins with 550–800 amino acids and are 
located in the extracellular region or appear in the lumen of 
endosomes, wherein they can recognize molecules secreted 
by invading pathogens [31].
Expression of TLR2 in innate immune cells appears dif-
ferentially regulated by inflammatory mediators. TLR2 lev-
els in monocytes are increased by IL-1, IL-10, and LPS, 
and decreased by TNF, IL-4, and IFN-g. TLR2 expression 
in purified granulocytes is also down-regulated by LPS and 
TNF, but strongly up-regulated by IL-10 [32]. Interestingly, 
studies investigating the expression of TLR2 in cultured 
mouse astrocytes were consistent in this respect, whereas 
other reports in other cell systems are contradictory. For 
example, Bsibsi et  al. suggested the presence of TLR2 
mRNA in human astrocytes, whereas Farina et al. were una-
ble to discover this molecule [33, 34]. Moreover, cytokine- 
or LPS-activated mouse brains showed TLR2 expression in 
microglia but not in astrocytes [35, 36]. Besides, expression 
of TLR2 is found in primary human oligodendrocytes [33], 
though the functional importance of TLR2 in this cell type 
is unclear.
In vitro or in vivo expression of astrocytic TLR4 also 
appears controversial. Reports have revealed that cul-
tured astrocytes require microglia to entirely respond to 
LPS in vitro. Furthermore, oxygen–glucose deprivation in 
mixed glial cultures comprising astrocytes and microglia 
induces expression of TLR4 in these cells. TLR4 expres-
sion was much lower in astrocytes than in microglia [37–39]. 
However, one study reported that TLR4 was expressed in 
astrocytes but at just a comparatively low ratio compared 
to microglia [38]. It was additionally examined whether pro-
inflammatory agents including LPS or IL-1β could modify 
TLR4 expression in microglia and astrocytes. Neither LPS 
nor IL-1β significantly affected the expression of TLR4 in 
astrocytes. In contrast, TLR4 expression in microglia was 
up-regulated by IL-1β but unaffected by LPS [40].
TLR signaling pathways
Pro-inflammatory cytokines and chemokines are considered 
as the final products of the TLR signaling pathway [41]. A 
total number of five different adaptor molecules are described 
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for TLRs: the myeloid differentiation primary response gene 
88 (MyD88), MyD88 adaptor-like protein (MAL), TIR-
domain-containing adaptor protein including interferon-β-
mediated transcription factor (TRIF), TRIF-related adaptor 
molecule (TRAM), and sterile-alpha and armadillo motif-
containing protein (SARM) [42]. These adaptor molecules are 
considered as recruiters for the initiation and stimulation of 
downstream kinases and transcription factors that are involved 
in inflammation and antiviral responses [43]. TLRs and their 
respective adaptors can also interact with the homologous TIR 
domains present in both TLRs and adaptor molecules. Based 
on the recruitment of particular adaptors, TLRs can thus con-
verge on two second messenger pathways: MyD88 dependent 
or MyD88 independent. Basically, MyD88 adaptor protein 
can activate signals of the MyD88-dependent pathway with 
all TLR family members involved with the exception of TLR3 
[22, 44]. TLR1/2/4/6 is also bound to MyD88 after success-
fully assembling with TIRAP/Mal [45, 46] and then, MyD88 
can activate the IL-1 receptor-associated kinase 4 (IRAK4). 
Moreover, MyD88 can recruit other members of the IRAK 
family, such as IRAK-1 that stimulates mitogen-activated pro-
tein kinase and the NF-κB pathway (Fig. 1) [47]. Formation 
of MyD88 and IRAKs complexes are likely to disassociate 
and react with tumor necrosis factor receptor-associated factor 
6 (TRAF6). TRAF6 together with an ubiquitin-conjugating 
enzyme 13 (Ubc13) and ubiquitin-conjugating enzyme E2 
variant 1 (Uev1A) can catalyze Lys-63 (K63)-linked poly-
ubiquitination which initiates the activation of a complex 
consisting of transforming growth factor-β-activated kinase 
(TAK1), TAK1-binding protein 1 (TAB1), and TAB2 lead-
ing to phosphorylation of TAK1 and TAB2/3 [48, 49]. As 
well, TAK1 activates the inhibitor of NF-κB (IκB)–kinase 
complex (IKK) which is composed of IKK-α, IKK-β, and 
IKK-γ (Fig. 1). This complex phosphorylates IκB and causes 
NF-κB dissociation and translocation to the nucleus and the 
subsequent pro-inflammatory cytokine gene expression such 
as interleukin 1 β (IL-1β), IL-6, and tumor necrosis factor-α 
(TNF-α) [22, 50]. NF-κB consists of p65 and p50 dimers that 
are inactive if present in the cytoplasm in association with 
IκB [51]. The second part of the TAK1 pathway is the acti-
vation of mitogen-activated protein kinases (MAPKs) which 
includes three families of p38 MAPKs, extracellular signal-
regulated kinases (ERKs), and c-Jun-N-terminal kinases 
(JNKs). Finally, MAP kinase is responsible for the forma-
tion of AP-1, another transcription factor complex inducing 
cytokine gene expression (Fig. 1) [50, 52, 53].
TLR4 is the only member of the TLR family that is able 
to trigger both MyD88- and TRIF-dependent signaling 
pathway-related genes [44]. LPS is considered an impor-
tant ligand which binds to TLR4 and leads to endosome 
formation resulting in TRAM translocation to cytosol and 
TRIF-dependent signaling pathway activation [50]. This 
pathway responds with TRAF3 expression and activation of 
the TANK-binding kinase/IκB kinase (TBK1/IKKi) complex 
which leads to the interferon regulatory factor (IRF), IRF3 
and IRF7, phosphorylation. The phosphorylated IRF3 and 
IRF7 dimer will then translocate to the nucleus and finally 
induce IFN gene expression [22, 45, 50]. TRAF6 is another 
target after TRIF downstream activation pathway which is 
activated by receptor interacting protein 1 (RIP1) followed 
by TAK1 complex and NF-κB (Fig. 1) [46, 49].
As well, suppressor of cytokine signaling (SOCS1) is 
known as a protein induced by cytokines and can negatively 
regulate cytokine-signaling pathway and directly down-
modulate the TLR-signaling pathway [54, 55]. SOCS1 also 
affects the TLR–NF-κB pathway and binds to the p65 subu-
nit of NF-κB to help ubiquitylation of p65. SOCS1 might 
regulate stress-activated MAPKs and finally lead to the 
suppression of MAL-dependent p65 phosphorylation and 
NF-κB transactivation [56, 57].
Moreover, a molecule family termed triggering receptors 
expressed on myeloid cells (TREM) can influence the down-
stream signaling pathway of the TLRs. TREM molecules have 
both activating and inhibitory receptors as regulatory factors 
playing a role in TLR-mediated inflammatory responses [58]. 
TREM-1 and TREM-2 can act on immune cells involved in 
innate immune responses. It was reported that TREM-1 expres-
sion increases during an infection in vivo and following TLR 
stimulation in vitro [59, 60]. Silencing of TREM-1 influences 
chemokine and cytokine production by elevating access to 
downstream signaling molecules involved in acute inflamma-
tion. This silencing did not change TRIF-mediated expression 
of INF indicating that TREM-1 has no main role in reinforc-
ing this TLR signaling pathway. However, the influence of 
TREM-1 silencing on CD14, MyD88, and other molecules in 
downstream signaling suggests reduced pro-inflammatory sign-
aling. These authors also noted significant reductions in MyD88 
and CD14 transcripts as well as in downstream molecules of 
the NF-κB pathway following LPS stimulation in the setting 
of TREM-1 silencing [61, 62]. The overexpression of surface-
associated TREM-1, TLR2, and TLR4 in  CD14hiCD16+ mono-
cytes approves this pro-inflammatory role. However, simultane-
ous stimulation of TREM-1 and TLRs induced synergistically 
cytokine production and amplified inflammatory signals [63]. 
TREM-2 exists in naive primary astrocytes and was induced 
by exposure with LPS, OGD, or HMGB-1. Thus, the activa-
tion of TREM-2, overexpression of DAP12, and intracellu-
lar adaptor of TREM-2 could partly inhibit the activation of 
NF-κB induced by LPS in purified astrocytic cultures. Expres-
sion of TLR4 could also increase the sensitivity of astroglial 
cells to ligands, thereby facilitating an astrocyte shift towards 
a pro-inflammatory status. Then TREM-2 could moderate this 
response by decreasing downstream NF-κB activation. There-
fore, TREM-2 and TLR4 expressions in astrocytes might con-
trol the sensitivity of astrocytes to TLR ligands by regulation 
of downstream NF-κB activation [39].
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TLRs and stroke
There is good evidence that TLRs and their ligands play an 
important role after brain ischemic injury. The inflamma-
tory responses in immune cells are mediated by TLRs sug-
gesting that these receptors contribute to induce ischemic 
damage. It is evident that resident cells such as astrocytes 
and microglia initiate the inflammatory cascades after 
cerebral ischemia by recognizing injury-associated mol-
ecules. Subsequently, infiltration of immune cells such as 
macrophages and neutrophils to the damaged area take 
place and a massive release of inflammatory cytokines, 
proteolytic enzymes, and other cytotoxic mediators can be 
observed [7, 64, 65]. Several prospective studies including 
rodent models have investigated the function of TLRs in 
cerebral ischemia and addressed the basic question which 
Fig. 1  TLR cell signaling pathways. TLR4 and the heterodimers of 
TLR2/TLR1 or TLR2/TLR6 located on the cell surface identify 
their respective ligands. TLR4 is the only member of the TLR family 
which is also located in endosomes. The intracellular TLRs, TLR3, 
TLR7, TLR8, TLR9 are also found in endosomes. Every TLR fam-
ily member, except TLR3, uses the MyD88-dependent signaling 
pathway. TRAP/Mal adaptor proteins bridge MyD88 to TLR1/6/2/4 
and promote their interactions with TRAF6. TRAF6 activates the 
complex of TAK1, TAB1, and TAB2/3. TAK1 activates both the 
IKK complex and MAPK. Complex of IKK which causes IκB phos-
phorylation resulting in the translocation of NF-κB to the nucleus 
where pro-inflammatory gene expression is triggered. p38, ERK, 
JNK induced by MAPKs cause the AP-1 nuclear translocation. TLR 
7/8 and 9 can activate MyD88 through two pathways: one pathway 
causes the translocation of IRF7 transcription factor to the nucleus 
and leads to type I IFN expression; the other pathway induces NF-κB 
as a downstream signaling molecule. TRIF is another adaptor pro-
tein which is recruited by TLR3 and TLR4 independently from the 
MyD88 pathway and leads to IRF3/IRF7 dimer translocation to the 
nucleus resulting in the expression of type I IFN. Furthermore, TRIF 
can interact with TRAF6 through an effect on RIP-1 which is fol-
lowed by NF-κB activation. SOCS1 can inhibit the TLR signaling 
pathway via impact on NF-κB and MAPK activity and phosphoryla-
tion of p65
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TLR subpopulations are essential for the progression of 
ischemic damage in the brain [66].
TLR2 has been shown to be involved in sterile inflamma-
tion like ischemic brain damage [66, 67]. TLR2 can also act 
on glial cells to secrete inflammatory factors and pro-inflam-
matory mediators which further propagate brain damage [68]. 
Recent studies have indicated that leukocyte infiltration into 
the damaged area via a disrupted blood–brain barrier (BBB) 
and the subsequent induction of apoptosis in neurons can be 
induced by TLR2 and reduced by TLR2 suppression [69]. 
TLR2 mRNA levels in resident microglia are increased fol-
lowing brain ischemia in mice [66]. Besides, TLR2 can bind 
to endogenous ligands after ischemic stroke [70, 71]. HMGB1, 
considered as an essential DAMP in ischemic damage, is 
localized in the cell nucleus and translocated into the cytosol 
after ischemic injury to stimulate TLR2. It has been reported 
that HMGB1 neutralizing antibodies reduce the infarct vol-
ume after MCAO [72–74]. Peroxiredoxin (Prx) family pro-
tein which is expressed in the injured area is another member 
of DAMPs with a neuroprotective role [75, 76]. Neurons of 
TLR2-deficient mice are also protected against cell death 
induced by an ischemia-like energy exclusion model. In addi-
tion, less CNS damage has been seen in TLR2-knockout 
mice following focal cerebral ischemia [66, 77]. Mice lacking 
TLR2 gene have shown less brain damage and neurological 
deficits after MCAO compared to wild-type mice revealing 
an up-regulation of TLR2 gene in the non-ischemic brain 
hemisphere [68, 77]. An up-regulation of the TLR2 gene has 
been also reported in an in vitro ischemia/reperfusion model 
in cultured microglia [78]. It should be noted that the activa-
tion of microglia occurs by the release of toxic cytokines such 
as IL-23 and IL-17 during ischemia/reperfusion. The inhibi-
tion of this pathway in microglia can result in a protection 
after ischemia. Besides, inflammatory signaling of TLR2 in 
the post-ischemic brain requires the scavenger receptor CD36. 
The lack of this receptor can suppress inflammation. These 
findings suggest that the TLR2–CD36 complex could act as a 
sensor of ischemia at the onset of death signals and is vital for 
the inflammatory responses [79]. Therefore, TLR2 suppres-
sion could be potentially considered as a future treatment for 
ischemic stroke [69]. Other members of the TLR family, i.e., 
TLR3 or TLR9, also appear to be involved in brain ischemia 
[80–82]. For example, Alex et al. found that TLR3 signaling 
lowers the release of inflammatory cytokines by NF-κB path-
way suppression in TLR3-knockout mice [82–85]. TLR4 is 
considered to play a pivotal role for the progression of infarct 
volume in the ischemic brain via its binding to the endog-
enous ligands like HMGB1 which then causes immune cell 
infiltration through BBB into the infarct area and its surround-
ing regions [70, 71, 73, 81, 86–88]. TLR4 gene expression 
is increased in neurons after cerebral ischemia accompanied 
by the enhancement of multiple inflammatory cytokines. 
Knockout of the TLR4 gene in neurons can thus improve their 
survival under glucose-deprived conditions [66]. This was also 
proven in TLR4-deficient mice which displayed less infarct 
volume compared to wild types [89–93]. Similarly, research-
ers revealed that TLR4-mutant mice had less expression of 
cyclooxygenase 2 (COX2), inducible nitric oxide synthase 
(iNOS), and IFN-g [89, 90, 92]. Moreover, it was suggested 
that LPS as a ligand of TLR4 could modulate this receptor [68, 
94]. It should be noted that TLR7 and 8 seem to be directly 
involved in inflammatory damage following ischemic stroke 
[80].
TLR2 and TLR4 are known to be more essential than 
other TLRs in the pathological development of ischemic 
brain damage [10]. Nalamolu et al. described the neuropro-
tective impact of simultaneous TLR2/TLR4 suppression 
under ischemic stroke conditions probably mediated by 
mitigating the induction of the pro-inflammatory cytokines 
TNF, IL-1, and IL-6 [95]. Therefore, TLR2 and TLR4 can 
be considered as interesting targets for stroke treatment. A 
better knowledge about the molecular structure, genetic vari-
ations, and modulation by several reagents of TLRs can help 
in future managing stroke prevalence and treatments.
TLR gene polymorphisms and stroke risk
There are reportedly several polymorphisms in TLR2 and 
TLR4 genes which may possibly change the risk for stroke. 
According to the National Center for Biotechnology Infor-
mation (NCBI) database, many single nucleotide polymor-
phisms (SNPs) exist in TLR2 and TLR4 genes including 
rs5743708, rs1927911, rs4986790, and TLR4-C119A [96, 
97]. TLR2 is located on chromosome 4 (4q31.3) with 5 
exons and rs5743708 transition is situated on exon 5 [98]. 
This polymorphism, a missense mutation, can lead to a glu-
tamine-to-arginine substitution at codon 735 (p.Arg753Gln). 
Besides, the rs1927911 variant is located on intron 1 of the 
TLR4 gene on chromosome 9 (9q33.1) [99]. Considered as a 
missense SNP, the rs4986790 is situated on exon 4 of TLR4 
with the substitution of glycine to aspartate at codon 299 
(p.Asp299Gly). In addition, the TLR4–C119A transversion 
is located on intron 1 of the TLR4 gene. Results from a 
previous study revealed that allele and genotype frequen-
cies of rs1927911 were significantly different between stroke 
and control groups, while rs5743708 was not reported to 
be different between these groups. For rs1927911, it was 
shown that fasting blood glucose, blood pressure, and levels 
of serum lipids were not significantly different among the 
various genotypes in stroke and control groups [96]. Lin 
et al. reported a significant association between A119C poly-
morphism and stroke risk and demonstrated that the TLR4-
119A allele might be a risk factor for ischemic stroke and it 
was also concluded that rs4986790 was a rare variation in 
the given study population [97].
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Pathogenic effects of gene polymorphisms can be 
variable and depend on the position of SNP on the gene, 
RNA, and protein sequences [100, 101]. The four afore-
mentioned SNPs may also influence molecular aspects of 
TLR2 and TLR4. As mentioned in (Table 1) and accord-
ing to the RNAsnp database, only the rs4986790 poly-
morphism appeared to be deleterious for the TLR4 RNA 
structure [102]. This polymorphism could reduce the 
minimum free energy of RNA, change the expression of 
interested gene, and consequently change the expression 
of the genes of interest (Fig. 2) [103–105]. It should be 
noted that rs5743708 and rs4986790 polymorphisms are 
non-synonymous SNPs. Generally, non-synonymous poly-
morphisms cause amino acid substitutions in the protein 
sequence [106, 107]. According to the SNPeffect database, 
rs5743708 transition is located in a helix region of TLR2, 
whereas the rs4986790 SNP is situated in an extended 
region of TLR4 protein (Fig. 3). In addition, the database 
records have predicted both rs5743708 and rs4986790 
SNPs as harmful polymorphisms that are likely to reduce 
protein stability [108]. Other databases including Poly-
Phen-2 [109], SNAP [110], SIFT [111], and SNPeffect 
[112] can also provide evidence that rs5743708 transi-
tion is deleterious. Despite the fact that PolyPhen-2, SIFT, 
PhD-SNP, and SNPs&GO [113] databases have predicted 
rs4986790 transition as a benign SNP for TLR4 molecule 
(Table 2), it could be concluded that damaging effects 
of rs4986790 could arise from alterations in TLR4 RNA 
structure, while harmful effects of rs5743708 were likely 
to be caused by changes in the protein structure of TLR2.
Neurosteroids as TLR modulators
Neurosteroids can be synthesized by both neurons and glial 
cells and act within CNS [114]. Neurosteroids synthesized 
by nervous tissue can act through their intracellular nuclear 
receptors thereby regulating gene expression [115]. Thus, 
they are able to protect the brain via an inhibition of TLR-
related pathways from damage [116]. The risk of stroke in 
women typically increases at post-menopause stage indicat-
ing the protective potentials of female sex hormones, i.e., 
estrogen and progesterone (EP) [117]. Generally, both ster-
oids are neuroprotective in the CNS under acute neurodegen-
erative and neuropathological conditions [118–121]. Ani-
mal and human studies have also shown that EP decreases 
post-stroke ischemic injury [122–125]. Vitamin D and its 
Table 1  Effects of SNPs on RNA structure of TLR2 and TLR4
p values less than 0.2 are considered to be significant
SNP Gene Folding 
window
Local region Distance p value
rs5743708 TLR2 3085–3485 3261–3316 0.0009 0.9718
rs1927911 TLR4 8395–8795 8566–8615 0.0188 0.6715
rs4986790 TLR4 827–1227 972–1036 0.1510 0.1203
C119A TLR4 5208–5608 5399–5606 0.0422 0.5465
Fig. 2  Secondary structure of RNA of human TLR4 before and after 
rs4986790 transition. Optimal secondary structure of global sequence 
(highlighted from 827 to 1227  nt) in the wild type with minimum 
free energy = − 129.20  kcal/mol (a) and mutant with minimum free 
energy = − 74.60 kcal/mol (b). The figure was modified from rnaSNP
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metabolites are also recognized as important neuroster-
oids that are capable to guard neurons following ischemia 
[126–128].
Estrogen
This hormone exerts its biological actions mainly through 
three different estrogen receptors (ERs) including ERα, 
ERβ, and G protein-coupled receptor 30 (GPR30) which 
are all expressed in the brain and linked to various molec-
ular pathways such as membrane-linked receptors and 
nuclear receptors [129, 130]. The modulation of neuroin-
flammation is considered as one the most important neu-
roprotective mechanisms of estrogens after brain ischemia 
[131]. Accordingly, studies have shown that estrogen 
decreases toxic damage to neurons and regulates neuro-
inflammatory processes via the modulation of glial cell 
function, and consequently reduces infarct volume when 
it is given after permanent or transient brain ischemia 
[11, 132–136]. 17β-Estradiol (E2) has been reported to 
suppress the release of cytokines and pro-inflammatory 
factors such as TNF-α, IFN-γ, and IL-17. Additionally, 
E2 can promote the release of the anti-inflammatory fac-
tors such as transforming growth factor beta (TGF-β) and 
IL-10 [137, 138]. Generally, E2 plays an important role 
for the TLR/NF-κB signaling pathway. It has been dem-
onstrated that TLR4 is down-regulated by E2. Moreover, 
TLR2 is significantly down-regulated in ERα mutant 
ovariectomized mice [139, 140]. Additional studies have 
indicated the neuroprotective effects of ERα following 
experimental ischemic damage through the interaction of 
ERα with IL-6 and NF-κB [141–145].
As mentioned above, E2 can act via ERα independent 
of its nuclear function by preventing NF-κB nuclear trans-
location. This demonstrates that E2–ERα signaling path-
ways play an important role in immediate-early inflamma-
tory response (Fig. 4a) [146]. E2 levels elevated in obesity 
and during pregnancy could also increase the expression 
of IκBα as an anti-inflammatory molecule. On the other 
hand, ERβ could block nuclear translocation of NF-κB in 
cerebral ischemia [147]. Elevated levels of TLR2, TLR4, 
and MyD88 mRNA, activated NF-κB, and also phosphoryl-
ated p65 in ovariectomized mice may be reversed by ERβ 
agonists (Fig. 4a) [139]. Moreover, estrogen treatment could 
reduce the expression of TNF-α after cerebral ischemia, 
Fig. 3  Partial three-dimensional structures of TLR2 and TLR4. The rs5743708 and rs4986790 substitutions are a helix domain of TLR2 (a) and 
an extend domain of TLR4 (b), respectively
Table 2  Effects of rs5743708 
and rs4986790 SNPs on protein 
structure
The “+” and “−” symbols show deleterious and benign effects, respectively
SNP Gene Motif position PolyPhen-2 SNAP SIFT SNPeffect PhD-SNP SNPs&GO
rs5743708 TLR2 Helix + + + + + −
rs4986790 TLR4 Extend − + − + − −
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although it has been reported that chronic administration of 
E2 stimulates TNF-α and pro-inflammatory cytokine release 
[148–150].
Pre-treatment of male rats with E2 in a MCAO model 
also showed a significant down-regulation of IL-1β and 
a lowering of infarct volume compared to non-treated 
males [151]. There are other reports showing IL-6 inhi-
bition and control of inflammation after E2 treatment in 
ischemic stroke [152]. Furthermore, E2 could boost the 
MAPK/ERK pathway which mediated neuroprotection 
and deprivation of this hormone modulates activation and 
expression of the p38 MAPK family members in the brain 
[153, 154]. In this respect, Koerner et al. revealed that 
estrogen replacement in ovariectomized mice could lead 
to temporal anti-inflammatory responses that were likely 
to induce immunosuppression [140]. Following brain 
ischemia, estrogen can also promote the formation of the 
resting microglia and astrocyte phenotype which reduce 
their activation, proliferation, and migration towards the 
damaged region and may be assumed responsible for the 
inhibition of glial-derived pro-inflammatory factors [122].
Progesterone
This neurosteroid appears to be neuroprotective in a vari-
ety of species including human particularly in neurode-
generative diseases, stroke, traumatic brain injury (TBI), 
and spinal cord injury. Generally, this hormone decreases 
neuronal loss and brain edema by down-regulating distinct 
inflammatory pathways [155–162]. Progesterone typically 
exerts its actions through progesterone receptors (PRs) 
such as classical isoforms of PR-A and PR-B which are 
found in the nucleus and operate as transcription factors 
via binding to progesterone response elements in the pro-
moter of gene. In addition, progesterone membrane recep-
tors also exist in the brain which transmit a wide variety 
of progesterone effects [162–165]. Both nuclear and mem-
brane PRs mediate progesterone-regulated responses in 
the brain affecting directly microglia, astrocytes, and neu-
rons [163]. This hormone can reduce inflammation after 
cerebral ischemia and TBI via modulating TLR signaling 
[116, 166]. Hua et al. showed that progesterone did not 
suppress the activation of TLR2 but rather promoted the 
Fig. 4  Effects of neurosteroids on TLR signaling pathways under 
ischemic conditions. a Estrogen/ER could increase IκB, also ERα 
could block NF-κB nuclear translocation. In the nucleus, ERα/β 
inhibits the expression of TLR2/4, and ERβ suppresses the p65 subu-
nit of NF-κB. Progesterone suppresses LPS-induced NF-kB activa-
tion by prevention of the phosphorylation of IκB and the p65 subu-
nit. Progesterone also blocks the expression of TLR2/4, increases the 
expression of IκB, and TLR9, and suppresses the transcription of the 
p65 gene. Estrogen/progesterone promote mitochondrial function by 
blocking of DAMP action and suppressing p38 MAPK activation. b 
Vitamin D3 binding to VDR leads to anti-inflammatory effects by 
suppressing phosphorylation of IκB, p38 MAPK and NF-κB translo-
cation to the nucleus and also by stimulation of SOCS1 which inhib-
its the TLR pathway. VD3 exerts a negative regulation of the phos-
phorylation of IκB by blocking ROS activity and suppressing the 
expression of TLR2/4 and NF-κB activity. Pro-inflammatory effects 
of VD3 occur via the down-regulation of TLR9 and by blocking of 
IL-6 expression. Up- and down-regulation of genes are depicted by ↑ 
and ↓ symbols
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expression of TLR9 [94, 116]. Furthermore, progester-
one and its metabolites regulate TLR4 and NF-κB signal 
transduction pathways after subarachnoid hemorrhage and 
ischemic brain damage [166, 167]. There is more infor-
mation available concerning the progesterone-mediated 
control of protective signaling cascades such as inhibition 
of LPS-induced NF-κB activation by blocking IκBα and 
suppressing p65 subunit phosphorylation, down-regulation 
of phosphorylation of the p38, JNK and ERK MAPKs in 
microglia [168], and attenuation of TLR2/4 expression and 
antagonizing NF-κB activity by increasing transcription 
of IκBα gene or suppression of p65 gene (Fig. 4a) [169, 
170]. It has also reported that progesterone controls IL-1β 
and TNF-α after TBI [171] and MCAO [172]. However, 
another report described that progesterone has no influ-
ence on the expression of IL-1β and TNF-α following 
brain injury [173].
In general, data suggest that a co-treatment of E2 with 
progesterone is more effective in the treatment of neuro-
degeneration than exposure to single steroids possibly due 
to their synergistic effects [174]. A combined EP treatment 
of cerebral cortex neurons appears to be more effective in 
preventing glucose serum deprivation (CGSD) and might 
be the result of direct and indirect interactions with micro-
glia [175–177]. EP treatment also promotes mitochondrial 
function by attenuating DAMP activity and blocking the 
TLR4/NF-κB pathway [176, 178–181].
The negative results of both clinical trials called SyN-
APSE and ProTECT III, which used neurosteroids and 
their derivatives as a treatment regimen created a lot of 
frustration in the field of steroid-mediated neuroprotection 
in the brain. The method for administration of progester-
one might be one reason for the failure. In the SyNAPSe 
III and ProTECT trials, natural progesterone has been used 
by continuous intravenous infusion to patients with TBI. 
However, none of the preclinical TBI trainings has used 
this method but instead subcutaneous or intraperitoneal 
injections [182]. In addition, large doses of progesterone 
were given in the clinical trials throughout. Only a few 
animal studies have tried dose–response relationships of 
progesterone and suggested that high doses of progester-
one might be less effective or even damaging after TBI 
[183]. Furthermore, the abrupt discontinuation of the 
intravenous progesterone administration and long-term 
treatment with progesterone after experimental TBI are 
more effective than a short-term treatment [184, 185]. 
Therefore, the design of the SyNAPSe and ProTECT III 
trials could imply some ideal options that were not always 
supported by existing preclinical outcomes [182].
Vitamin D
Vitamin D3 (cholecalciferol) is mainly synthesized in the 
skin or is intestinally absorbed. Cholecalciferol can be ini-
tially metabolized in the liver into calcifediol (25-hydrox-
ycholecalciferol) and then in the kidney into calcitriol 
(1,25(OH)2D3). Calcitriol is considered the most impor-
tant biologically active metabolite of vitamin D. It has 
also been identified as a neuroprotective factor for stroke 
[126, 186–188]. Vitamin D is structurally similar to classi-
cal steroid hormones and mainly acts via nuclear receptors 
thereby regulating inflammatory genes expressed in mac-
rophages and T lymphocytes [189–191]. Vitamin D can 
also inhibit inflammatory responses and may elicit anti-
inflammatory pathways by acting through specific vitamin 
D receptors (VDR) [192] which are found in immune cells 
[193]. There are additional functions of vitamin D along 
with its influence on immune cells which can be benefi-
cial under pathological conditions including regulation of 
apoptosis and cell cycle [188]. Calcitriol can also modu-
late TLR signaling through SOCS1 stimulation, prevent the 
phosphorylation of p38 MAPK, and inhibit NF-κB activ-
ity (Fig. 4b) [193–197]. IkB phosphorylation is a result of 
mitochondrial dysfunction which occurs as a result of an 
elevation of reactive oxygen species (ROS) in mitochon-
dria of injured cells after hypoxia. It has been suggested 
that calcitriol/VDR can directly interfere with the IkB/
NF-κB complex or IKKβ, thus preventing the transloca-
tion of p65 into the cell nucleus [198, 199]. Treatment of 
human monocytes and macrophages with vitamin D3 can 
also reduce the expression of TLR2/4 and block NF-κB 
within the nucleus (Fig. 4b) [200, 201]. Vitamin  D3 can 
further minimize the release of TNF-α, IL-6, and IL-1b in 
human/murine macrophages and monocytes following LPS 
stimulation [201]. Interestingly, TLR2 can promote VDR 
expression and TLR agonists can elevate the conversion 
of calcifediol into calcitriol by regulating the expression 
of 1α-hydroxylase (1αOHase) [202, 203]. Recent evidence 
from animal studies and clinical trials suggest that vita-
min D deficiency is correlated with several inflammatory 
diseases and increased infarct volumes in stroke [193, 
204, 205]. Moreover, treatment with vitamin D has been 
reported to cause TLR9 down-regulation in monocytes and 
subsequently lower IL-6 release [206]. As well, it has been 
revealed that co-treatment of vitamin D and progesterone 
in TBI, an ischemic in vitro neuronal model, and a cerebral 
ischemia animal model results in better outcomes by modu-
lation of the TLR4/NF-κB signaling cascade [207, 208].
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Conclusion
This review article focused on aspects of TLR signaling 
during acute neuropathological challenges in the brain and 
highlighted the potential neuroprotective capacity of estro-
gen, progesterone and vitamin D3 and their putative interac-
tions with TLR signaling pathways after cerebral ischemia 
and TBI. In particular, TLR2 and TLR4 signaling appeared 
to be pivotal for controlling pathogenic immune responses 
following stroke. All three hormones were able to modulate 
TLR2 and TLR4 signal transduction. Thus, these steroids 
and the vitamin can be considered as therapeutic options 
for stroke therapy.
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